Living donor liver transplantation using ABO-incompatible grafts for chronic and acute liver failure
Surgery Today · 2025
DOI: 10.1007/s00595-025-03100-3 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Surgery Today, 2025. Verfasst von Toru Ikegami und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hepatobiliary and Pancreas Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo, 105-8461, Japan. toruikegamiji…. Hauptthemen laut MEDLINE: Liver Transplantation, ABO Blood-Group System, Living Donors, Blood Group Incompatibility. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Kakenhi (Grants-in-Aid for Scientific Research).
Abstract (Originalsprache)
The introduction of rituximab, an anti-CD20 antibody, has changed the treatment strategies and outcomes for ABO-incompatible living donor liver transplantation (ABOi-LDLT) dramatically. Rituximab targets the CD20-positive B-cells that would differentiate into plasma cells, producing antibodies against A or B antigen-expressing cells and causing microvascular multiple thrombosis and graft necrosis or diffuse bile-duct necrosis. Now, the universal desensitization of the ABOi combination between the donor and recipient is performed by rituximab, and ABOi-LDLT has become the treatment of choice for end-stage liver disease. However, because rituximab takes 1-3 weeks to mediate its effects, complicated strategies are necessary to perform ABOi-LDLT for acute liver failure. For example, high-dose intravenous immunoglobulin (IVIG) or bortezomib may be used to alleviate the elevation of isoagglutinin titers. The diagnosis and treatment of antibody-mediated rejection (AMR) remain challenging. Treatment options include plasma exchange, high-dose IVIG, and bortezomib, but the optimal strategies have not been identified. In this review, we discuss standard ABOi-LDLT for chronic liver disease, ABOi-LDLT for acute liver failure, and the diagnosis and treatment of AMR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hepatobiliary and Pancreas Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo, 105-8461, Japan. toruikegamijikei@jikei.ac.jp.
- Division of Hepatobiliary and Pancreas Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo, 105-8461, Japan.
Förderung
- Kakenhi (Grants-in-Aid for Scientific Research)
Zitieren
APA
Ikegami, T., Tsunematsu, M., Furukawa, K., Onda, S., Matsumoto, M., Shirai, Y., & Haruki, K. (2025). Living donor liver transplantation using ABO-incompatible grafts for chronic and acute liver failure. Surgery Today. https://doi.org/10.1007/s00595-025-03100-3
Vancouver
Ikegami T, Tsunematsu M, Furukawa K, Onda S, Matsumoto M, Shirai Y, et al. Living donor liver transplantation using ABO-incompatible grafts for chronic and acute liver failure. Surgery Today. 2025. doi:10.1007/s00595-025-03100-3
BibTeX
@article{Ikegami2025,
author = {Ikegami, Toru and Tsunematsu, Masashi and Furukawa, Kenei and Onda, Shinji and Matsumoto, Michinori and Shirai, Yoshihiro and Haruki, Koichiro},
title = {Living donor liver transplantation using ABO-incompatible grafts for chronic and acute liver failure},
journal = {Surgery Today},
year = {2025},
doi = {10.1007/s00595-025-03100-3}
}
EUVIMED